Regen BioPharma, Inc. (RGBP) Fair Value 2026

RGBP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (47/100)

Quick Summary — As of 2026-08-27, Regen BioPharma, Inc. (RGBP) trades at $0.00. QOC: 3.9/10. Value Trap Risk: 47/100 (WARN). 1/13 models active.

Key Facts

Ticker
RGBP
Price
$0.00
Quality Score
3.9/10
Value Trap Risk
47/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 47 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give RGBP?

1 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.00 -23.4%

All Models Active

All 1 models are displayed above.

What Is Regen BioPharma, Inc. (RGBP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Regen BioPharma, Inc.'s intrinsic value is estimated at $0.00, suggesting the stock is overvalued at its current price of $0.00. With 1 out of 1 models flagging downside (-23.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About RGBP?

1 of 13 models are currently active for RGBP. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does RGBP Rank in Biotechnology?

Among 620 Biotechnology stocks, RGBP ranks #537 by Quality of Company score. CirclFi's QOC score of 3.9/10 evaluates 32 fundamental signals. A score of 3.9 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Regen BioPharma, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating RGBP should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RGBP a Value Trap?

CirclFi's Value Trap algorithm assigns RGBP a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Regen BioPharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Regen BioPharma, Inc.'s fundamental quality profile registers 3.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGBP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RGBP's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Regen BioPharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

JSPRJasper Therapeutics, Inc.QOC 3.9ADILAdial Pharmaceuticals, Inc.QOC 3.9PKTXProtoKinetix, IncorporatedQOC 3.9DWTXDogwood Therapeutics, Inc.QOC 3.9BCABBioAtla, Inc.QOC 4.0MBRXMoleculin Biotech, Inc.QOC 3.9FENCFennec Pharmaceuticals Inc.QOC 6.7HYFTMindWalk Holdings Corp.QOC 5.4RLMDRelmada Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: JSPR · ADIL · PKTX · DWTX · BCAB · MBRX · FENC · HYFT · RLMD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RGBP?

6 companies across all industries closest to RGBP’s Quality of Company score of 3.9/10.

TLSSTransportation and Logistics Systems, Inc.QOC 3.9GWTIGreenway Technologies, Inc.QOC 3.9EZRAReliance Global Group, Inc.QOC 3.9MOBQMobiquity Technologies, Inc.QOC 3.9WHKWhiteHawk Minerals Corp.QOC 3.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TLSS · GWTI · EZRA · MOBQ · WHK · NVDA

Where Does RGBP Sit in CirclFi's Biotechnology Rankings?

RGBP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Regen BioPharma, Inc.’s Valuation?

What is Regen BioPharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Regen BioPharma, Inc. (RGBP). The Quality of Company score is 3.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGBP overvalued or undervalued right now?

At $0.00, 0 of 1 active models suggest RGBP may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Regen BioPharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.9 mean for RGBP?

Regen BioPharma, Inc.'s QOC of 3.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RGBP?

CirclFi analyzes RGBP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is RGBP a value trap in 2026?

Regen BioPharma, Inc.'s Value Trap score is 47/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Regen BioPharma, Inc. (RGBP) a Quality of Company score of 3.9/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/RGBP/ · Methodology
Primary sources for this RGBP valuation
  • Financial statements: Regen BioPharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001589150) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RGBP as of ; valuations recomputed .